Ascendis Pharma AS Asset Resilience Ratio
Ascendis Pharma AS asset resilience ratio. Ascendis Pharma AS (A71) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Ascendis Pharma AS (A71) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Ascendis Pharma AS (2020–2024)
Asset resilience ratio of Ascendis Pharma AS from 2020 to 2024. This chart shows how Ascendis Pharma AS's Asset Resilience Ratio has changed over time. Read Ascendis Pharma AS (A71) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Ascendis Pharma AS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Ascendis Pharma AS balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Ascendis Pharma AS maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Ascendis Pharma AS Industry Peers by Asset Resilience Ratio
Compare Ascendis Pharma AS's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Ascendis Pharma AS Asset Resilience Ratio by Year (2020–2024)
Ascendis Pharma AS asset resilience ratio by year from 2020 to 2024. The table below shows the annual Asset Resilience Ratio data for Ascendis Pharma AS.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | €0.00 ≈ $0.00 |
€1.18 Billion ≈ $1.38 Billion |
-- |
| 2023-12-31 | 0.88% | €7.28 Million ≈ $8.51 Million |
€825.59 Million ≈ $965.20 Million |
-25.79pp |
| 2022-12-31 | 26.68% | €290.69 Million ≈ $339.84 Million |
€1.09 Billion ≈ $1.27 Billion |
+4.94pp |
| 2021-12-31 | 21.73% | €235.80 Million ≈ $275.67 Million |
€1.08 Billion ≈ $1.27 Billion |
+8.03pp |
| 2020-12-31 | 13.70% | €134.28 Million ≈ $156.99 Million |
€979.79 Million ≈ $1.15 Billion |
-- |
About Ascendis Pharma AS
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is a… Read more